Transthyretin Amyloidosis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

FDA approval · 2021-06-01
FDA Approved: VYNDAMAX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for VYNDAMAX (tafamidis) submitted by Pfizer Laboratories Div Pfizer Inc.